home / stock / lexx / lexx quote
Last: | $2.35 |
---|---|
Change Percent: | 0.91% |
Open: | $2.17 |
Close: | $2.35 |
High: | $2.45 |
Low: | $2.17 |
Volume: | 172,105 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.35 | $2.17 | $2.35 | $2.45 | $2.17 | 172,105 | 04-26-2024 |
$2.19 | $2.15 | $2.19 | $2.3 | $2.15 | 22,122 | 04-25-2024 |
$2.2 | $2.2 | $2.2 | $2.28 | $2.18 | 97,910 | 04-24-2024 |
$2.24 | $2.24 | $2.24 | $2.3 | $2.2 | 53,982 | 04-23-2024 |
$2.265 | $2.19 | $2.265 | $2.29 | $2.19 | 34,458 | 04-22-2024 |
$2.2 | $2.26 | $2.2 | $2.29 | $2.15 | 61,647 | 04-19-2024 |
$2.25 | $2.34 | $2.25 | $2.41 | $2.22 | 124,708 | 04-18-2024 |
$2.34 | $2.3 | $2.34 | $2.73 | $2.25 | 461,093 | 04-17-2024 |
$2.31 | $1.98 | $2.31 | $2.35 | $1.85 | 306,531 | 04-16-2024 |
$1.99 | $2.12 | $1.99 | $2.14 | $1.91 | 315,206 | 04-15-2024 |
$2.12 | $2.64 | $2.12 | $2.64 | $2.12 | 456,031 | 04-12-2024 |
$2.51 | $2.6 | $2.51 | $2.72 | $2.5 | 249,700 | 04-11-2024 |
$2.66 | $2.65 | $2.66 | $2.79 | $2.6 | 143,405 | 04-10-2024 |
$2.7 | $3.03 | $2.7 | $3.03 | $2.64 | 246,969 | 04-09-2024 |
$2.96 | $3.18 | $2.96 | $3.18 | $2.93 | 155,258 | 04-08-2024 |
$3.05 | $3.12 | $3.05 | $3.29 | $3.05 | 124,644 | 04-05-2024 |
$3.19 | $3.29 | $3.19 | $3.48 | $3.17 | 270,527 | 04-04-2024 |
$3.41 | $3.38 | $3.41 | $3.5694 | $3.23 | 246,703 | 04-03-2024 |
$3.47 | $3.36 | $3.47 | $3.5 | $3.32 | 134,543 | 04-02-2024 |
$3.42 | $3.82 | $3.42 | $3.82 | $3.25 | 159,197 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful a...
Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans...
(TheNewswire) Human Pilot Study #2 (GLP-1-H24-2) Approved Kelowna, British Columbia – TheNewswire – April 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...